Breaking News, Financial News

Financial Report: Kendle

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kendle

4Q Revenues: $86.4 million (+64)

4Q Loss: $1.8 million (earnings were $5.2 million in 4Q2005)

FY Revenues: $283.5 million (+40%)

FY Earnings: $20.0 million (+16%)

Comments: New business awards were $164 million in the quarter. For the year, total business authorizations, which consist of signed backlog and verbally awarded business, totaled a record $659 million. Loss in the quarter includes an $8.2 million impairment charge related to the August acquisition of the Phase II-IV clinical services business of Charles River Laboratories International, Inc.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters